课题基金 / 基金详情

BENZO A PYRENE MUTAGENIC MECHANISMS

BENZO A PYRENE MUTAGENIC MECHANISMS
苯并芘诱变机制
批准号:
6055891
负责人:
EDWARD L LOECHLER
金额:
$26.98万
依托单位国家:
美国
项目类别:
财政年份:
1985
资助国家:
美国
项目状态:
已结题
起止时间:
1985-06-30 至 2001-08-31

项目摘要

项目成果

EDWARD L LOECHLER的其他基金

相似基金

相关文献

中文摘要
翻译
苯并[a]芘是一种有效的诱变剂/致癌物
英文摘要
Benzo[a]pyrene is a potent mutagen/carcinogen that is metabolically activated inside cells, including to its (+)-anti-7,8-diol-9,10-epoxide [(+)-anti-B[a]PDE], which gives DNA adducts, principally at N2-Gua. We showed that (+)-anti-B[a]PDE induces base substitution, frameshifts, insertion and deletions (supF gene of plasmid pUB3 in E. coli). The question we are addressing is: how is (+)-anti-B[a]PDE able to induce such a diverse array of mutations? Our working hypothesis is that adduct mutational complexity is due to adduct conformational complexity, and that the major adduct [(+)-trans-anti-B[a]P-N2-Gua] is able to induce the majority of these mutations. Adduct conformation--and, thereby, mutation-- may be controlled by various factors, notably, DNA sequence context. (1) We showed that little of mutagenesis can be attributed to AP sites formation from (+)-anti-B[a]PDE adducts. We showed that trans-(+)-anti- B[a]P-N2-Gua can be unstable in ds (but not ss) DNA and gives its corresponding tetraols. Although this unexpected reaction is interesting, it is unlikely to be at the root of any important mutational observations. (2) Using adduct site-specific methods, we showed previously that (+)- trans-anti-B[a]P-N2-Gua induced G->T mutations in a 5'-TG-3' sequence context, which correlated with our studies showing that (+)-anti-B[a]PDE itself induced principally G->T mutations in 5'-TG-3' sequence contexts suggesting a mechanistic link. 3. In supF (+)-anti-B[a]PDE induced mostly G->A in one sequence context (5'-CGT-3'). In preliminary experiments we show that (+)-trans-anti- B[a]P-N2-Gua also induces G->A mutations in this sequence context. 4. In supF we identified a sequence (5'-CGG-3') where the mutagenic specificity seemed to be changeable, being G->T in some cases and G->T, A & C in others. If our hypothesis is correct, then this might be a conformationally sensitive site. We now show that trans-(+)-anti-B[a]P- N2-Gua indeed can change its pattern of mutations in this sequence context; for example, the mutational pattern following PEG treatment (predominantly G->T) is different than following ethanol precipitation (a mixture of G->T, A & C mutations). Herein we propose to gather further evidence that adduct conformational complexity is at the root of adduct mutational complexity. We also seek to establish sequence contexts where (+)-trans-anti-B[a]P-N2-Gua can induce each individual mutation (e.g., G->T only, G->A only, and G->C only), as a prelude to doing structural studies to determine what conformation is responsible for what mutation and why. The initiation of parallel studies with shuttle vectors in human cells is also proposed.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Research Conference:Mutagenesis and Carcinogenesis
  • 批准号:
    6479700
  • 项目类别:
  • 资助金额:
    $1.1万
  • 财政年份:
    2002
  • 负责人:
    EDWARD L LOECHLER
  • 依托单位:
MUTAGENIC PATHWAYS INVOLVING 5-METHYLCYTOSINE
INTERSTRAND CROSSLINKS--REPLICATION, REPAIR, MUTATIONS
  • 批准号:
    2093199
  • 项目类别:
  • 资助金额:
    $14.09万
  • 财政年份:
    1993
  • 负责人:
    EDWARD L LOECHLER
  • 依托单位:
INTERSTRAND CROSSLINKS--REPLICATION, REPAIR, MUTATIONS
  • 批准号:
    3193201
  • 项目类别:
  • 资助金额:
    $13.53万
  • 财政年份:
    1993
  • 负责人:
    EDWARD L LOECHLER
  • 依托单位:
国内基金
海外基金
重编程L-苏氨酸生产菌株Escherichia coli THRH高效合成L-异亮氨酸的底盘菌株设计与构建
  • 批准号:
    22508213
  • 项目类别:
    青年科学基金项目(C类)
  • 资助金额:
    30.00万元
  • 批准年份:
    2025
  • 负责人:
    赵振强
  • 依托单位:
肠道Escherichia coli BW25113增殖调控C1GALT1介导IgA肾病发生的作用与机制
asr基因调控酸诱导的Escherichia coli O157:H7形成VBNC状态的机制研究
  • 批准号:
    32302245
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    30.00万元
  • 批准年份:
    2023
  • 负责人:
    潘寒姁
  • 依托单位:
小肠中Escherichia coli分泌细菌毒素诱导肠屏障损伤及细菌易位在炎症性肠病中的机制研究
  • 批准号:
    82371775
  • 项目类别:
    面上项目
  • 资助金额:
    46万元
  • 批准年份:
    2023
  • 负责人:
    朱慧媛
  • 依托单位: